Dual-modality image-guided surgery of prostate cancer with a radiolabeled fluorescent anti-PSMA monoclonal antibody

Journal of Nuclear Medicine

Volumn 55, Issue 6, 2014, Pages 995-1001

  Lütje, Susanne ^a   Rijpkema, Mark ^a   Franssen, Gerben M ^a   Fracasso, Giulio ^b   Helfrich, Wijnand ^c   Eek, Annemarie ^a   Oyen, Wim J ^a   Colombatti, Marco ^b   Boerman, Otto C ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF VERONA   (Italy)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

D2B IgG; Dual modality imaging; Fluorescence imaging; IRDye800CW; Prostate cancer; PSMA

Indexed keywords

4 ISOTHIOCYANATOBENZYL DIETHYLENETRIAMINEPENTAACETIC ACID; ACETIC ACID DERIVATIVE; INDIUM 111; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY D2B; N HYDROXYSUCCINIMIDE; PENTETIC ACID; PROSTATE SPECIFIC MEMBRANE ANTIGEN; UNCLASSIFIED DRUG; BENZENESULFONIC ACID DERIVATIVE; FLUORESCENT DYE; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; INDIUM; INDOLE DERIVATIVE; IRDYE 800CW; MEMBRANE ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; BIOACCUMULATION; CANCER LOCALIZATION; CONTROLLED STUDY; DIAGNOSTIC IMAGING; FLUORESCENCE IMAGING; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MALE; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NEAR INFRARED IMAGING SYSTEM; NONHUMAN; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROSTATE CANCER; RADIATION DOSE DISTRIBUTION; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ANIMAL; BAGG ALBINO MOUSE; BINDING COMPETITION; CELL TRANSFORMATION; CHEMISTRY; COMPUTER ASSISTED SURGERY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; HUMAN; IMMUNOLOGY; PATHOLOGY; PROCEDURES; PROSTATIC NEOPLASMS; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, SURFACE; BENZENESULFONATES; BINDING, COMPETITIVE; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; FLUORESCENT DYES; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; INDIUM RADIOISOTOPES; INDOLES; ISOTOPE LABELING; MALE; MICE; MICE, INBRED BALB C; OPTICAL IMAGING; PROSTATIC NEOPLASMS; SURGERY, COMPUTER-ASSISTED; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84903123791     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.114.138180     Document Type: Article

References (24)

1. Heidenreich A, Bellmunt J, Bolla M, et al.; European Association of Urology. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol. 2011;59:61-71.
2. Eastham JA, Kuroiwa K, Ohori M, et al. Prognostic significance of location of positive margins in radical prostatectomy specimens. Urology. 2007;70:965-969. (Pubitemid 350192610)
3. Eastham JA, Kattan MW, Riedel E, et al. Variations among individual surgeons in the rate of positive surgical margins in radical prostatectomy specimens. J Urol. 2003;170:2292-2295. (Pubitemid 37413978)
4. Yossepowitch O, Briganti A, Eastham JA, et al. Positive surgical margins after radical prostatectomy: a systematic review and contemporary update. Eur Urol. 2014;65:303-313.
5. Stephenson AJ, Eggener SE, Hernandez AV, et al. Do margins matter? The influence of positive surgical margins on prostate cancer-specific mortality. Eur Urol. 2014;65:675-680.
6. Kelderhouse LE, Chelvam V, Wayua C, et al. Development of tumor-targeted near infrared probes for fluorescence guided surgery. Bioconjug Chem. 2013;24:1075-1080.
7. van Dam GM, Themelis G, Crane LM, et al. Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-a targeting: first in-human results. Nat Med. 2011;17:1315-1319.
8. Fomina N, McFearin CL, Sermsakdi M, Morachis JM, Almutairi A. Low power, biologically benign NIR light triggers polymer disassembly. Macromolecules. 2011;44:8590-8597.
9. Ross JS, Sheehan CE, Fisher HA, et al. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res. 2003;9:6357-6362. (Pubitemid 38031820)
10. Colombatti M, Fracasso G, Cingarlini S, Canevari S, Figini M, inventors; Università Degli Studi Di Verona, Fondazione IRCCS "Istituto Nazionale Dei Tumori", assignee. Isolated monoclonal antibody or fragment thereof binding prostate specific membrane antigen, conjugates and uses thereof. International Patent Application PCT/IB2009/005326. October 29, 2009.
11. Castelletti D, Fracasso G, Alfalah M, Cingarlini S, Colombatti M, Naim HY. Apical transport and folding of prostate-specific membrane antigen occurs independent of glycan processing. J Biol Chem. 2006;281:3505-3512. (Pubitemid 43845966)
12. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA Jr. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods. 1984;72:77-89. (Pubitemid 14091996)
13. Heskamp S, van Laarhoven HW, Molkenboer-Kuenen JD, et al. ImmunoSPECT and immunoPET of IGF-1R expression with the radiolabeled antibody R1507 in a triple-negative breast cancer model. J Nucl Med. 2010;51:1565-1572.
14. van den Berg NS, Valdés-Olmos RA, van der Poel HG, van Leeuwen FW. Sentinel lymph node biopsy for prostate cancer: a hybrid approach. J Nucl Med. 2013;54:493-496.
15. van der Poel HG, Buckle T, Brouwer OR, Valdés Olmos RA, van Leeuwen FW. Intraoperative laparoscopic fluorescence guidance to the sentinel lymph node in prostate cancer patients: clinical proof of concept of an integrated functional imaging approach using a multimodal tracer. Eur Urol. 2011;60:826-833.
16. Gleysteen JP, Duncan RD, Magnuson JS, Skipper JB, Zinn K, Rosenthal EL. Fluorescently labeled cetuximab to evaluate head and neck cancer response to treatment. Cancer Biol Ther. 2007;6:1181-1185. (Pubitemid 351590369)
17. Lee SB, Hassan M, Fisher R, et al. Affibody molecules for in vivo characterization of HER2-positive tumors by near-infrared imaging. Clin Cancer Res. 2008;14:3840-3849.
18. Withrow KP, Newman JR, Skipper JB, et al. Assessment of bevacizumab conjugated to Cy5.5 for detection of head and neck cancer xenografts. Technol Cancer Res Treat. 2008;7:61-66. (Pubitemid 351238697)
19. Liu T, Wu LY, Hopkins MR, Choi JK, Berkman CE. A targeted low molecular weight near-infrared fluorescent probe for prostate cancer. Bioorg Med Chem Lett. 2010;20:7124-7126.
20. Nakajima T, Mitsunaga M, Bander NH, Heston WD, Choyke PL, Kobayashi H. Targeted, activatable, in vivo fluorescence imaging of prostate-specific membrane antigen (PSMA) positive tumors using the quenched humanized J591 antibody-indocyanine green (ICG) conjugate. Bioconjug Chem. 2011;22:1700-1705.
21. Chen Y, Dhara S, Banerjee SR, et al. A low molecular weight PSMA-based fluorescent imaging agent for cancer. Biochem Biophys Res Commun. 2009;390:624-629.
22. Banerjee SR, Pullambhatla M, Byun Y, et al. Sequential SPECT and optical imaging of experimental models of prostate cancer with a dual modality inhibitor of the prostate-specific membrane antigen. Angew Chem Int Ed Engl. 2011;50:9167-9170.
23. Cohen R, Stammes MA, de Roos IH, Stigter-van Walsum M, Visser GW, van Dongen GA. Inert coupling of IRDye800CW to monoclonal antibodies for clinical optical imaging of tumor targets. EJNMMI Res. 2011;1:31.
24. Kovar JL, Simpson MA, Schutz-Geschwender A, Olive DM. A systematic approach to the development of fluorescent contrast agents for optical imaging of mouse cancer models. Anal Biochem. 2007;367:1-12. (Pubitemid 46938663)